Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Mantle Cell Lymphoma and Non-Hodgkin Lymphomas at the American Society of Hematology (ASH) Annual Meeting

52% overall response rate in mantle cell lymphoma patients previously treated with a covalent BTK inhibitor 83% of responding mantle cell lymphoma patients remain in response and on therapy 68% overall response rate in patients with Waldenström's macroglobulinemia, 69% of whom were previously